Related Experiment Video
Updated: Jul 11, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
LINC00092 Enhances LPP Expression to Repress Thyroid Cancer Development via Sponging miR-542-3p
1General Practice Section, Wuhan University of Science and Technology Hospital, Wuhan, China.
Abstract:
LINC00092 is poorly expressed in Thyroid cancer (TC), while its role in TC tumorigenesis is still elusive. This study aimed to reveal the role and regulatory mechanism of LINC00092 in TC.RNA immunoprecipitation and dual luciferase reporter assays were employed to ascertain the relationships among lipoma preferred partner (LPP), miR-542-3p, and LINC00092. qRT-PCR analysis was performed to detect their expression levels in TC. LPP protein productions were evaluated via western blotting. CCK-8, transwell, and colony formation assays were done to estimate TC cells' biological functions. A murine xenograft model was built to observe tumor formation in vivo.LINC00092 overexpression decreased the expression levels of miR-542-3p, and LPP was targeted by miR-542-3p. In TC cells and tissues, the elevation of miR-542-3p, and low amounts of LINC00092 and LPP can be observed. Both LINC00092 and SPAG6 were considered as the antineoplastic factors in TC since their overexpression dramatically repressed TC cells' invasive and proliferative potentials, while miR-542-3p exerted the opposite functions in TC. The ectopic expression of LINC00092 also suppressed tumor growth in vivo. In addition, it revealed that miR-542-3p upregulation reversed LINC00092 overexpression-mediated effects on TC cells. At the same time, the enhanced influences of TC cells caused by miR-542-3p upregulation could be attenuated by the enforced LPP.This study innovatively reveals that LINC00092 acts as an antineoplastic lncRNA to restrain the development of TC via regulating miR-542-3p/LPP. The findings of this study may provide a prospective drug target on LINC00092/miR-542-3p/LPP axis for the treatment of TC.
Insights
Long non-coding RNA LINC00092 restrains thyroid cancer (TC) development by regulating miR-542-3p and lipoma preferred partner (LPP). Overexpressing LINC00092 inhibits TC cell proliferation and invasion, offering a potential therapeutic target.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Thyroid cancer (TC) progression is influenced by poorly understood genetic factors.
- The role of long non-coding RNA LINC00092 in thyroid cancer tumorigenesis remains largely elusive.
- Identifying novel regulatory mechanisms is crucial for developing effective TC treatments.
Purpose of the Study:
- To elucidate the role of LINC00092 in thyroid cancer development.
- To investigate the regulatory mechanism involving LINC00092, miR-542-3p, and lipoma preferred partner (LPP) in TC.
- To assess the potential of the LINC00092/miR-542-3p/LPP axis as a therapeutic target for TC.
Main Methods:
- Quantitative reverse transcription polymerase chain reaction (qRT-PCR) to assess expression levels of LINC00092, miR-542-3p, and LPP in TC tissues and cells.
- RNA immunoprecipitation and dual-luciferase reporter assays to confirm interactions between LINC00092, miR-542-3p, and LPP.
- Cell proliferation, invasion, and colony formation assays, alongside a murine xenograft model, to evaluate the functional impact of LINC00092 and miR-542-3p on TC in vitro and in vivo.
Main Results:
- LINC00092 expression was significantly downregulated in TC tissues and cells, while miR-542-3p was upregulated.
- LINC00092 overexpression suppressed TC cell proliferation, invasion, and tumor growth in vivo, acting as an antineoplastic factor.
- miR-542-3p targeted LPP and exerted opposite functions to LINC00092, promoting TC progression; its effects were reversed by LINC00092 and attenuated by LPP.
Conclusions:
- LINC00092 functions as an antineoplastic long non-coding RNA in thyroid cancer.
- The study reveals a novel regulatory pathway where LINC00092 restrains TC development by modulating the miR-542-3p/LPP axis.
- The LINC00092/miR-542-3p/LPP pathway represents a promising therapeutic target for thyroid cancer treatment.
Related Concept Videos
Abnormal Proliferation
MicroRNAs
lncRNA - Long Non-coding RNAs
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Cell Specific Gene Expression

